Artificial intelligence-aided clinical annotation of a large multi-cancer genomic dataset

[1]  N. Schultz,et al.  Implications of Selection Bias Due to Delayed Study Entry in Clinical Genomic Studies. , 2021, JAMA oncology.

[2]  J. Warner,et al.  Correlation Between Surrogate End Points and Overall Survival in a Multi-institutional Clinicogenomic Cohort of Patients With Non–Small Cell Lung or Colorectal Cancer , 2021, JAMA network open.

[3]  Byron C. Wallace,et al.  Does BERT Pretrained on Clinical Notes Reveal Sensitive Data? , 2021, NAACL.

[4]  Marco Piñón,et al.  I Overview , 2020, The Diaries and Letters of Lord Woolton 1940-1945.

[5]  Y. Bang,et al.  Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study. , 2020, The Lancet. Oncology.

[6]  E. V. Van Allen,et al.  Natural Language Processing to Ascertain Cancer Outcomes From Medical Oncologist Notes. , 2020, JCO clinical cancer informatics.

[7]  Ashton C. Berger,et al.  Interplay of somatic alterations and immune infiltration modulates response to PD-1 blockade in advanced clear cell renal cell carcinoma , 2020, Nature Medicine.

[8]  A. Dechartres,et al.  Progression-free survival as a surrogate for overall survival in oncology trials: a methodological systematic review , 2020, British Journal of Cancer.

[9]  A. Stenzinger,et al.  Establishing guidelines to harmonize tumor mutational burden (TMB): in silico assessment of variation in TMB quantification across diagnostic platforms: phase I of the Friends of Cancer Research TMB Harmonization Project , 2020, Journal for ImmunoTherapy of Cancer.

[10]  N. Schultz,et al.  Harmonization of Tumor Mutational Burden Quantification and Association With Response to Immune Checkpoint Blockade in Non-Small-Cell Lung Cancer. , 2019, JCO precision oncology.

[11]  Kenneth L Kehl,et al.  Assessment of Deep Natural Language Processing in Ascertaining Oncologic Outcomes From Radiology Reports. , 2019, JAMA oncology.

[12]  David Bourque,et al.  Association of Patient Characteristics and Tumor Genomics With Clinical Outcomes Among Patients With Non–Small Cell Lung Cancer Using a Clinicogenomic Database , 2019, JAMA.

[13]  T A Chan,et al.  Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[14]  Christopher Grob,et al.  Real-world application , 2018, Inventory Management in Multi-Echelon Networks.

[15]  Donavan T. Cheng,et al.  Mutational Landscape of Metastatic Cancer Revealed from Prospective Clinical Sequencing of 10,000 Patients , 2017, Nature Medicine.

[16]  L. Macconaill,et al.  Validation of OncoPanel: A Targeted Next-Generation Sequencing Assay for the Detection of Somatic Variants in Cancer. , 2017, Archives of pathology & laboratory medicine.

[17]  Marian Harris,et al.  Institutional implementation of clinical tumor profiling on an unselected cancer population. , 2016, JCI insight.

[18]  R. Yelensky,et al.  Cancer Therapy Directed by Comprehensive Genomic Profiling: A Single Center Study. , 2016, Cancer research.

[19]  Martín Abadi,et al.  TensorFlow: Large-Scale Machine Learning on Heterogeneous Distributed Systems , 2016, ArXiv.

[20]  Sandeep Sahu,et al.  OncDRS: An integrative clinical and genomic data platform for enabling translational research and precision medicine , 2015, Applied & translational genomics.

[21]  Martin L. Miller,et al.  Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer , 2015, Science.

[22]  Joshua M. Stuart,et al.  The Cancer Genome Atlas Pan-Cancer analysis project , 2013, Nature Genetics.

[23]  Levi A Garraway,et al.  Precision oncology: an overview. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  J. Crowley,et al.  Overview: Progression-Free Survival as an Endpoint in Clinical Trials with Solid Tumors , 2013, Clinical Cancer Research.

[25]  M Buyse,et al.  Two or three year disease-free survival (DFS) as a primary end-point in stage III adjuvant colon cancer trials with fluoropyrimidines with or without oxaliplatin or irinotecan: data from 12,676 patients from MOSAIC, X-ACT, PETACC-3, C-06, C-07 and C89803. , 2011, European journal of cancer.

[26]  R. Labianca,et al.  Evidence for cure by adjuvant therapy in colon cancer: observations based on individual patient data from 20,898 patients on 18 randomized trials. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  Daniel J Sargent,et al.  Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: individual patient data from 20,898 patients on 18 randomized trials. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  R. Gill,et al.  Cox's regression model for counting processes: a large sample study : (preprint) , 1982 .

[29]  AACR Project GENIE: Powering Precision Medicine through an International Consortium. , 2017, Cancer discovery.

[30]  W. Youden,et al.  Index for rating diagnostic tests , 1950, Cancer.